A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants

被引:33
|
作者
Khan, David D. [1 ]
Lagerback, Pernilla [2 ]
Cao, Sha [3 ]
Lustig, Ulrika [3 ]
Nielsen, Elisabet I. [1 ]
Cars, Otto [2 ]
Hughes, Diarmaid [3 ]
Andersson, Dan I. [3 ]
Friberg, Lena E. [1 ]
机构
[1] Uppsala Univ, Dept Pharmaceut Biosci, Uppsala, Sweden
[2] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[3] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden
关键词
PHARMACOKINETIC-PHARMACODYNAMIC MODEL; ANTIMICROBIAL RESISTANCE; IN-VITRO; CIPROFLOXACIN; AGENTS; COLISTIN; PHARMACOMETRICS; STABILITY; EVOLUTION; RESPONSES;
D O I
10.1093/jac/dkv233
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: In silico pharmacokinetic/pharmacodynamic (PK/PD) models can be developed based on data from in vitro time-kill experiments and can provide valuable information to guide dosing of antibiotics. The aim was to develop a mechanism-based in silico model that can describe in vitro time-kill experiments of Escherichia coli MG1655 WT and six isogenic mutants exposed to ciprofloxacin and to identify relationships that may be used to simplify future characterizations in a similar setting. Methods: In this study, we developed a mechanism-based PK/PD model describing killing kinetics for E. coli following exposure to ciprofloxacin. WT and six well-characterized mutants, with one to four clinically relevant resistance mutations each, were exposed to a wide range of static ciprofloxacin concentrations. Results: The developed model includes susceptible growing bacteria, less susceptible (pre-existing resistant) growing bacteria, non-susceptible non-growing bacteria and non-colony-forming non-growing bacteria. The non-colony-forming state was likely due to formation of filaments and was needed to describe data close to the MIC. A common model structure with different potency for bacterial killing (EC50) for each strain successfully characterized the time-kill curves for both WT and the six E. coli mutants. Conclusions: The model-derived mutant-specific EC50 estimates were highly correlated (r(2) = 0.99) with the experimentally determined MICs, implying that the in vitro time-kill profile of a mutant strain is reasonably well predictable by the MIC alone based on the model.
引用
收藏
页码:3051 / 3060
页数:10
相关论文
共 28 条
  • [21] Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A1 receptor agonists in rats:: Prediction of tissue-dependent efficacy in vivo
    Van der Graaf, PH
    Van Schaick, EA
    Visser, SAG
    De Greef, HJMM
    Ijzerman, AP
    Danhof, M
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1999, 290 (02): : 702 - 709
  • [22] Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients
    Chee M. Ng
    S. Bai
    C. H. Takimoto
    M. T. Tang
    A. W. Tolcher
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 207 - 217
  • [23] Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients
    Ng, Chee M.
    Bai, S.
    Takimoto, C. H.
    Tang, M. T.
    Tolcher, A. W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (02) : 207 - 217
  • [24] A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria
    Kristoffersson, Anders N.
    Bissantz, Caterina
    Okujava, Rusudan
    Haldimann, Andreas
    Walter, Isabelle
    Shi, Tianlai
    Zampaloni, Claudia
    Nielsen, Elisabet, I
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (02) : 400 - 408
  • [25] Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure
    Wu, B.
    Derendorf, H.
    PHARMAZIE, 2010, 65 (06): : 417 - 420
  • [26] A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development
    Udata, Chandrasekhar
    Garzone, Pamela D.
    Gumbiner, Barry
    Joh, Tenshang
    Liang, Hong
    Liao, Kai-Hsin
    Williams, Jason H.
    Meng, Xu
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (07): : 855 - 864
  • [27] Development of a mechanism-based pharmacokinetic/target occupancy/pharmacodynamic model to characterize the effect on neutrophil count by JNJ-61610588, an anti-VISTA monoclonal antibody, in cynomolgus monkeys
    Jiang, Xiling
    Niu, Jin
    Leu, Jocelyn
    Singh, Indrajeet
    Snyder, Linda A.
    Sun, Yu-Nien
    Wang, Weirong
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S120 - S121
  • [28] A MECHANISM-BASED PHARMACOKINETIC-PHARMACODYNAMIC MODEL FOR RN316 (PF-04950615), A HUMANIZED MAB AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9), AND ITS APPLICATION IN EARLY CLINICAL DEVELOPMENT.
    Udata, C.
    Garzone, P.
    Gumbiner, B.
    Joh, T.
    Forgues, P.
    Levisetti, M.
    Vana, A.
    Liang, H.
    Bollini, S.
    Wan, H.
    Liao, K.
    Williams, J.
    Meng, X.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S51 - S52